获取途径

作者

Xingsheng Wang, Xinxin Zhang, Li Sun, Guangsheng Gao, Yun Li

作者单位

com. ⁵ Intensive Care Unit, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. shenggao163@16 com. ⁷ Intensive Care Unit, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. yunlee2022@16 com. ⁹ Central Hospital Affiliated to Shandong First Medical University, NO. 105 Jiefang Road, Jinan, 250000, Shandong, China. yunlee2022@16 com. ⁸ Intensive Care Unit, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. yunlee2022@16 Affiliations ¹ Intensive Care Unit, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. ² Intensive Care Unit, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. ³ Department of Emergency Medicine, Fuyang People's Hospital, Fuyang, Anhui, China. ⁴ Intensive Care Unit, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. shenggao163@16 com. ⁶ Central Hospital Affiliated to Shandong First Medical University, NO. 105 Jiefang Road, Jinan, 250000, Shandong, China. shenggao163@16 com.

刊名

European journal of medical research

年份

2022

卷号

Vol.27 No.1

页码

206

ISSN

2047-783X

关键词

Acute lung injury IL-17A Inflammatory pathway Secukinumab Sepsis.

摘要

Secukinumab is a specific neutralizing antibody for IL-17A. At present, numerous studies have confirmed the important role of IL-17A in sepsis, but the role of secukinumab in sepsis has not been studied. The present study explored the protective effect and underlying mechanism of secukinumab in severe sepsis model rats. We established a severe sepsis rat model using cecal ligation and puncture . The optimal dose of secukinumab was determined by observing the 7-day survival rate of severe sepsis ...更多

Secukinumab is a specific neutralizing antibody for IL-17A. At present, numerous studies have confirmed the important role of IL-17A in sepsis, but the role of secukinumab in sepsis has not been studied. The present study explored the protective effect and underlying mechanism of secukinumab in severe sepsis model rats. We established a severe sepsis rat model using cecal ligation and puncture . The optimal dose of secukinumab was determined by observing the 7-day survival rate of severe sepsis model rats. The expression levels of TNF-α, IL-6, and IL-17A in plasma and lung tissue were determined by enzyme-linked immunosorbent assay. The degree of pathological damage to lung tissue was evaluated by hematoxylin-eosin staining and pathological damage scale. The expressions of IKBα/NFκB pathway proteins and downstream-related inflammatory factors were detected by western blotting and real-time quantitative polymerase chain reaction . Our results show that high-dose secukinumab can inhibit the activation of the IKBα/NFκB inflammatory pathway by neutralizing IL-17A and reducing the gene expression of pathway-related inflammatory cytokines, thereby reducing the levels of inflammatory cytokines in lung tissue and plasma, thereby reducing the damage of lung tissue in severe sepsis model rats and improving the systemic inflammatory response.收起

文献类型

期刊